volume 17, issue 3, P157-159 1996
DOI: 10.2500/108854196779165021
View full text
|
Sign up to set email alerts
|
Share

Abstract: Intranasally administered corticosteroids have a wide margin of safety and are the mainstay of treatment for patients with moderate to severe allergic rhinitis, nonallergic rhinitis, and nasal polyposis. Long term use in recommended dosages has not caused nasal mucosal atrophy or hypothalamic-pituitary-adrenal (HPA) suppression. In practice, although fluticasone propionate and flunisolide appear to be twice as potent as beclomethasone dipropionate, there is little, if any, difference in therapeutic effectivene…

Expand abstract